Alembic Pharma gets USFDA nod for Parkinson’s disease treatment drugs

Alembic Pharma gets USFDA nod for Parkinson’s disease treatment drugs

The company has received approval from the USFDA for its abbreviated new drug application Carbidopa and Levodopa extended-release tablets

Economy:-Alembic Pharmaceuticals on Thursday said it has gotten endorsement from the US wellbeing controller for Carbidopa and Levodopa expanded discharge tablets, utilized for treatment of Parkinson’s malady.
The affirmed items are restoratively equal to the reference recorded medication Sinemet CR tablets of Merck Sharp and Dohme Corp.
The organization has gotten endorsement from the US Food and Drug Administration (USFDA) for its abridged new medication application Carbidopa and Levodopa broadened discharge tablets in the qualities of 2.5 mg/100 mg and 50mg/200 mg, Alembic said in a BSE documenting.
Citing IQVIA deals information, the organization said the two items had an expected market size of $24 million for a year finished December 2018.
The organization said it currently has a sum of 94 truncated new medication application (ANDA) endorsements from the USFDA.
Offers of Alembic Pharmaceuticals were exchanging at Rs 511.05 each, down 0.08 percent, on the BSE.

Comments

Popular posts from this blog

49-day lockdown necessary to stop coronavirus resurgence in India: Study

India’s life expectancy rises to 68.7 years: National Health Profile 2019

Covid-19 relief: RBI cuts repo 75 bps; defers term-loan EMIs for 3 months